Creating a device to efficiently capture and enrich T cells for cell therapies
Official title: High efficiency microfluidic device for large scale engineered cell therapy manufacturing
Funded at Indee, INC · NIH-10693775 · Data updated 2026-11-12
This study is testing a new device that helps separate important immune cells from blood more easily and safely, making it better for creating treatments like CAR-T therapy for people with certain health conditions.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indee, INC NIH-funded |
| Lab location | 1 site (Berkeley, UNITED STATES) |
| Project start | September 6, 2023 |
| Project end | September 5, 2025 |
| Funding year | 2023 |
| Award (this year) | $295,924 |
| NIH project number | 1R43GM150293-01 |
| Project ID | NIH-10693775 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals requiring engineered cell therapies, such as those with certain types of cancers or autoimmune diseases.
✕Less likely to help
Patients who do not require engineered cell therapies or those whose conditions do not involve T cell-based treatments may not benefit from this research.
What this research studies
This research focuses on developing a microfluidic device designed to gently and effectively isolate CD3+ T cells from whole blood, which are crucial for engineered cell therapies like CAR-T. The device aims to streamline the manufacturing process by minimizing human intervention and maximizing cell viability and yield. By optimizing the device to work with existing technology, the goal is to enhance the efficiency of producing high-quality engineered immune cells for therapeutic use.
Why it matters
Potential benefit: If successful, this research could significantly reduce the time and cost associated with producing engineered cell therapies, making them more accessible to patients.
How similar studies have gone: Other research has shown promise in using microfluidic technologies for cell isolation and engineering, indicating a potential for success in this novel approach.
Where this research is happening
-
Indee, INC
Berkeley, United States Active
Researchers
- Principal investigator: Pawell, Ryan — Indee, INC
- Study coordinator: Pawell, Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.